Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.

KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner.

This milestone represents a step in Doseology’s operational evolution—establishing the commercial infrastructure, manufacturing capacity, and regulatory foundation required to support the Company’s transition from development of its oral stimulant pouches to full market readiness.

“This is much more than a manufacturing agreement, it’s a defining moment as it enables Doseology to move from R&D to commercial deployment,” said Tim Corkum, President & COO of Doseology. “Through Doseology USA Inc., we’ve secured an American partner that delivers the scale, quality, and integrity we require as we prepare to enter the oral stimulant pouch market.”

Extensive Diligence Across North America

Doseology’s leadership conducted on-site reviews, operational assessments, and compliance audits across numerous facilities throughout the United States and Canada.

After rigorous evaluation, the Company selected a partner recognized for:

• Certified & Compliant Production: FDA-registered, GMP-certified, and ISO 9001:2015-approved facility ensuring pharmaceutical-grade quality and safety.
• Turnkey Manufacturing Expertise: End-to-end solutions spanning formulation, ingredient sourcing, blending, pouch filling, packaging, and logistics.
• Oral Pouch Specialization: Precision control across nicotine, caffeine, and nootropic pouch formats—customizable by dosage, moisture, and flavour.
• Rigorous Quality & Regulatory Systems: Built-in QA, traceability, and labeling practices fully aligned with FDA and ISO standards.
• Scalable, Low-Risk Partnership Model: Flexible production volumes that accommodate early pilot runs, regional launches, and high-volume commercial production designed to minimize capital investment while accelerating go-to-market.